Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers

Modern Pathology

Volumn 29, Issue 8, 2016, Pages 810-823

  Yao, Min ^a   Yu, Elaine ^a   Staggs, Vincent ^b   Fan, Fang ^a   Cheng, Nikki ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; CALCIUM BINDING PROTEIN; CCL2 PROTEIN, HUMAN; FSP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STROMA; TUMOR VOLUME; BREAST TUMOR; CANCER GRADING; CHEMISTRY; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; LOBULAR CARCINOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STROMA CELL; TIME FACTOR; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; UPREGULATION;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOKINE CCL2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROMAL CELLS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84964635549     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.78     Document Type: Article

References (57)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics 2012. CA Cancer J Clin 2015; 65: 87-108.
2. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol 2011; 223: 307-317.
3. Harkins B, Geyer CE Jr. Overcoming treatment challenges in advanced breast cancer. Semin Oncol Nurs 2007; 23: S10-S16.
4. Amar S, Roy V, Perez EA. Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat 2009; 114: 413-422.
5. Koca E, Kuzan TY, Dizdar O, et al. Outcomes of locally advanced breast cancer patients with 4/ = 10 positive axillary lymph nodes. Med Oncol 2013; 30: 615.
6. Cheng YC, Ueno NT. Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer 2012; 19: 191-199.
7. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
8. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
9. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
10. Aleskandarany MA, Green AR, Benhasouna AA, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 2012; 14: R3.
11. Munzone E, Curigliano G, Colleoni M. Tailoring adjuvant treatments for the individual patient with luminal breast cancer. Hematol Oncol Clin North Am 2013; 27: 703-714, vii-viii
12. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16(Suppl 1): 1-11.
13. Hasebe T, Mukai K, Tsuda H, et al. New prognostic histological parameter of invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus. Pathol Int 2000; 50: 263-272.
14. Anastassiades OT, Pryce DM. Fibrosis as in indication of time in infiltrating breast cancer and its importance in prognosis. Br J Cancer 1974; 29: 232-239.
15. Mezi S, Aloise G, Marzullo A, et al. Prognostic significance of desmoplasia in breast carcinoma. A preliminary clinical study. G Chir 1997; 18: 263-268.
16. Strutz F, Okada H, Lo CW, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995; 130: 393-405.
17. Sugimoto H, Mundel TM, Kieran MW, et al. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006; 5: 1640-1646.
18. Medrek C, Ponten F, Jirstrom K, et al. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012; 12: 306.
19. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
20. Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008; 13: 394-406.
21. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
22. Loeffler M, Kruger JA, Niethammer AG, et al. Targeting tumor-Associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116: 1955-1962.
23. Brennen WN, Rosen DM, Wang H, et al. Targeting carcinoma-Associated fibroblasts within the tumor stroma with a fibroblast activation protein-Activated prodrug. J Natl Cancer Inst 2012; 104: 1320-1334.
24. Abrous-Anane S, Savignoni A, Daveau C, et al. Management of inflammatory breast cancer after neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 1055-1063.
25. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-527.
26. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6: 17-32.
27. Balkwill FR. The chemokine system and cancer. J Pathol 2012; 226: 148-157.
28. White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation-Therapeutic opportunities and pharmacological challenges. Pharmacol Rev 2013; 65: 47-89.
29. Greaves NS, Ashcroft KJ, Baguneid M, et al. Current understanding of molecular and cellular mechanisms in fibroplasia and angiogenesis during acute wound healing. J Dermatol Sci 2013; 72: 206-217.
30. Fang WB, Jokar I, Chytil A, et al. Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression. Clin Exp Metastasis 2011; 28: 351-366.
31. Fang WB, Jokar I, Zou A, et al. CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- And p42/44 mitogen-Activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem 2012; 287: 36593-36608.
32. Fujimoto H, Sangai T, Ishii G, et al. Stromal MCP-1 in mammary tumors induces tumor-Associated macrophage infiltration and contributes to tumor progression. Int J Cancer 2009; 125: 1276-1284.
33. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-Tumour metastasis. Nature 2011; 475: 222-225.
34. Hembruff SL, Jokar I, Yang L, et al. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia 2010; 12: 425-433.
35. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282-3289.
36. Valkovic T, Fuckar D, Stifter S, et al. Macrophage level is not affected by monocyte chemotactic protein-1 in invasive ductal breast carcinoma. J Cancer Res Clin Oncol 2005; 131: 453-458.
37. Fang WB, Yao M, Jokar I, et al. The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. Breast Cancer Res Treat 2015; 150: 309-320.
38. Zou A, Lambert D, Yeh H, et al. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-beta signaling proteins. BMC Cancer 2014; 14: 781.
39. Rizzardi AE, Johnson AT, Vogel RI, et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012; 7: 42.
40. Abadi A, Yavari P, Dehghani-Arani M, et al. Cox models survival analysis based on breast cancer treatments. Iran J Cancer Prev 2014; 7: 124-129.
41. Morrow M, Krontiras H. Who should not receive chemotherapy?. Data from American databases and trials. J Natl Cancer Inst Monogr 2001; 109-113.
42. Maskarinec G, Pagano I, Lurie G, et al. Factors affecting survival among women with breast cancer in Hawaii. J Womens Health (Larchmt) 2011; 20: 231-237.
43. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165: 1267-1273.
44. Hunter RJ, Navo MA, Thaker PH, et al. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35: 69-78.
45. Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, et al. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2015; 2: 322-329.
46. Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol 2015; 2: 330-339.
47. Waks AG, King TA, Winer EP. Timeliness in breast cancer treatment-The sooner, the better. JAMA Oncol 2015; 2: 302-304.
48. Kwan ML, Kushi LH, Weltzien E, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009; 11: R31.
49. Rezai M, Kellersmann S, Knispel S, et al. Translating the concept of intrinsic subtypes into an oncoplastic cohort of more than 1000 patients - predictors of recurrence and survival. Breast 2015; 24: 384-390.
50. Dehqanzada ZA, Storrer CE, Hueman MT, et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006; 12: 478-486.
51. Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol 2006; 37: 1217-1226.
52. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
53. Saji H, Koike M, Yamori T, et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001; 92: 1085-1091.
54. Park SY, Kim HM, Koo JS. Differential expression of cancer-Associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat 2015; 149: 727-741.
55. Laoui D, Movahedi K, Van Overmeire E, et al. Tumorassociated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol 2011; 55: 861-867.
56. Stoger JL, Gijbels MJ, van der Velden S, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 2012; 225: 461-468.
57. Sousa S, Brion R, Lintunen M, et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res 2015; 17: 101.